BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 250 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2021. The put-call ratio across all filers is 0.73 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $16,000 | +6.7% | 112 | -9.7% | 0.00% | 0.0% |
| Q1 2022 | $15,000 | +36.4% | 124 | +59.0% | 0.00% | 0.0% |
| Q4 2021 | $11,000 | -15.4% | 78 | -15.2% | 0.00% | 0.0% |
| Q3 2021 | $13,000 | +62.5% | 92 | +17.9% | 0.00% | +100.0% |
| Q2 2021 | $8,000 | +166.7% | 78 | +95.0% | 0.00% | 0.0% |
| Q1 2021 | $3,000 | – | 40 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |